Differences in the longevity of topo IIα and topo IIβ drug-stabilized cleavable complexes and the relationship to drug sensitivity

Cancer Chemotherapy and Pharmacology

Volumn 53, Issue 2, 2004, Pages 155-162

  Errington, Fiona ^a   Willmore, Elaine ^a   Leontiou, Chrysoula ^a   Tilby, Michael J ^a   Austin, Caroline A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Cleavable complex; DNA; Etoposide; mAMSA; Mitoxantrone; Topoisomerase II

Indexed keywords

AGAROSE; AMSACRINE; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) ALPHA; DNA TOPOISOMERASE (ATP HYDROLYSING) BETA; ETOPOSIDE; ISOPROTEIN; MITOXANTRONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DISSOCIATION; DNA DETERMINATION; DRUG SENSITIVITY; DRUG STABILITY; EMBRYO; ENZYME ASSAY; FIBROBLAST; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; TIME;

AMSACRINE; ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA, NEOPLASM; DNA-BINDING PROTEINS; ETOPOSIDE; FIBROBLASTS; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT ANTIBODY TECHNIQUE; FLUORESCENT DYES; HALF-LIFE; ISOENZYMES; KINETICS; MICE; MITOXANTRONE;

EID: 0442282173     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0701-1     Document Type: Article

References (25)

1. Austin CA, Marsh KL (1998) Eukaryotic DNA topoisomerase IIβ. Bioessays 20:215
2. Austin CA, Sng J, Patel S, Fisher LM (1993) Novel HeLa topoisomerase II is the IIβ isoform: complete coding sequence and homology with other type II topoisomerases. Biochim Biophys Acta 1172:283
3. Bailly JD, Skladanowski A, Bettaieb A, Mansat V, Larsen AK, Laurent G (1997) Natural resistance of acute myeloid leukemia cell lines to mitoxantrone is associated with lack of apoptosis. Leukemia 11:1523
4. Caldecott K, Banks G, Jeggo P (1990) DNA double-strand break repair pathways and cellular tolerance to inhibitors of topoisomerase II. Cancer Res 50:5778
5. Capranico G, Binaschi M (1998) DNA sequence selectivity of topoisomerases and topoisomerase poisons. Biochim Biophys Acta 1400:185
6. Chen C, Fuscoe JC, Liu O, Relling MV (1996) Etoposide causes illegitimate V (D) J recombination in human lymphoid leukemic cells. Blood 86:2210
7. Covey JM, Kohn KW, Kerrigan D, Tilchen EJ, Pommier Y (1988) Topoisomerase II-mediated DNA damage produced by 4′-(9-acridinylamino)- methanesulfon-m-anisidide and related acridines in L1210 cells and isolated nuclei: relation to cytotoxicity. Cancer Res 48:860
8. Cowell IG, Willmore E, Chalton D, Marsh KL, Jazrawi E, Fisher LM, Austin CA (1998) Nuclear distribution of human DNA topoisomerase IIβ: a nuclear targeting signal residues in the 116-residue C-terminal tail. Exp Cell Res 243:232
9. Errington F, Willmore E, Tilby MJ, Li L, Li G, Li W, Baguley BC, Austin CA (1999) Murine transgenic cells lacking DNA topoisomerase IIβ are resistant to acridine and mitoxantrone: analysis of cytotoxicity and cleavable complex formation. Mol Pharmacol 56:1309
10. Fox ME, Smith PJ (1990) Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone. Cancer Res 50:5813
11. Frank AJ, Procter SJ, Tilby MJ (1996) Detection and quantification of melphalan-DNA adducts at the single cell level in hematopoietic tumor cells. Blood 88:977
12. Harker WG, Slade DL, Drake FH, Parr RL (1991) Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase IIβ isoform. Biochemistry 30:9953
13. Hazelhurst LA, Foley NE, Gleason-Guzman MC, Hacker MP, Cress AE, Greenberger LW, de Jong MC, Dalton WS (1999) Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Res 59:1021
14. Hsiang, Y, Liu LF (1989) Evidence for the reversibility of cellular DNA lesion induced by mammalian topoisomerase II poisons. J Biol Chem 264:9713
15. Long BH, Musial ST, Brattain MG (1985) Single-and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide. Cancer Res 45:3106
16. Osheroff N (1989) Effect of antineoplastic agents on the DNA cleavage/religation of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide. Biochemistry 28:6157
17. Pommier Y, Zwelling LA, Kao-Shan C, Whang-Peng J, Bradley MO (1985) Correlations between intercalator-induced DNA strand breaks and sister chromatid exchanges, mutations, and cytotoxicity in Chinese hamster cells. Cancer Res 45:3143
18. Pommier Y, Leteurtre F, Fesen MR, Fujimori A, Bertrand R, Solary E, Kohlhagen G, Kohn KW (1994) Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 12:530
19. Strumberg D, Nitiss JL, Rose A, Nicklaus MC, Pommier Y (1999) Mutation of a conserved serine residue in a quinolone-resistant type II topoisomerase alters the enzyme-DNA and drug interactions. J Biol Chem 274:7292-7301
20. Suzuki H, Tarumoto Y, Ohsawa M (1997) Topoisomerase II inhibitors fail to induce chromosome-type aberrations in etoposide-resistant cells: evidence for essential contribution of the cleavable complex formation to the induction of chromosome-type aberrations. Mutagenesis 12:29
21. Tan KB, Dorman TE, Falls KM, Chung TDY, Mirabelli CK, Crooke ST, Mao J (1992) Topoisomerase IIα and topoisomerase IIβ genes: characterization and mapping to human chromosome 17 and 3, respectively. Cancer Res 52:231
22. Wang JC (1996) DNA Topoisomerases. Annu Rev Biochem 65:635
23. Willmore E, Frank AJ, Padget K, Tilby MJ, Austin CA (1998) Etoposide targets topoisomerase IIα and IIβ in leukemic cells: isoform-specific cleavable complexes visualised and quantified in situ by a novel immunofluorescence technique. Mol Pharmacol 53:78
24. Zwelling LA, Michaels S, Erickson LC, Ungerleider RS, Nichols M, Kohn KW (1981) Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4′-(9- acridinylamino)methanesulfon-m-anisidide and adriamycin. Biochemistry 20:6553
25. Zwelling LA, Estey E, Bakic M, Silberman L, Chan D (1987) Topoisomerase II as a target of antileukemic drugs. NCI Monographs 4:79